WO2018208108A1 - Protéine dkk1 présente spécifiquement dans des lymphocytes t régulateurs et son utilisation - Google Patents

Protéine dkk1 présente spécifiquement dans des lymphocytes t régulateurs et son utilisation Download PDF

Info

Publication number
WO2018208108A1
WO2018208108A1 PCT/KR2018/005398 KR2018005398W WO2018208108A1 WO 2018208108 A1 WO2018208108 A1 WO 2018208108A1 KR 2018005398 W KR2018005398 W KR 2018005398W WO 2018208108 A1 WO2018208108 A1 WO 2018208108A1
Authority
WO
WIPO (PCT)
Prior art keywords
dkk1
present
seq
immune
surface protein
Prior art date
Application number
PCT/KR2018/005398
Other languages
English (en)
Korean (ko)
Inventor
김정호
김범석
Original Assignee
주식회사 굳티셀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 굳티셀 filed Critical 주식회사 굳티셀
Priority to CN201880031227.9A priority Critical patent/CN110799212A/zh
Priority to JP2019561863A priority patent/JP2020519268A/ja
Publication of WO2018208108A1 publication Critical patent/WO2018208108A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Definitions

  • the present invention relates to DKK1 (Dickkopf-1) proteins, antibodies specific thereto, and uses thereof, which are specifically present on the surface of regulatory T cells (Treg cells), among immune cells.
  • DKK1 Dickkopf-1
  • T cells are immune cells that are produced in the bone marrow and mature in the thymus, and function to regulate antibody production of B cells or to control the functions of innate immune cells.
  • the T cells also called T lymphocytes, act not only as a helper for other immune cells, but also destroy direct invading substances.
  • immune cells One of the most important functions of immune cells is that the immune response is suppressed against the antigenic substances that make up the self surrounding the immune cells, while the immune response is recognized and recognized for non-self antigenic substances.
  • Immune cells induce no response to self antigens through developmental death, induction of mutations in receptors specific for self antigens, or inactivation of immune cells that recognize self antigens. This is called immunologic unresponsiveness or tolerance. Failure to self-tolerance induces an immune response to self antigens, which can lead to disease, which is called autoimmune disease.
  • the regulatory T cells control the function of conventional T cells to induce an excessive immune response or self tolerance.
  • the function and number of regulatory T cells are markedly reduced. Inability to perform their functions properly has been reported. Therefore, in patients with autoimmune diseases and chronic inflammatory diseases, returning regulatory T cells to normal levels of function and numbers may be one of the treatment methods.
  • One object of the present invention is to provide a DKK1 (Dickkopf-1) protein or antigenic determinant thereof specifically present on the surface of regulatory T cells.
  • DKK1 Dickkopf-1
  • Another object of the present invention is to provide an antibody specific for the DKK1 protein specifically present on the surface of the regulatory T cells.
  • Still another object of the present invention is to provide regulatory T cells in which DKK1 protein is expressed on the cell surface.
  • Another object of the present invention is to provide a method for screening an immunosuppressant or immune activator.
  • Another object of the present invention is to provide a method for diagnosing an immune related disease.
  • the inventors have discovered a DKK1 (Dickkopf-1) protein that is specifically present on the surface of immune cells, in particular regulatory T cells, selected epitopes of the protein, immune cells expressing the DKK1 protein, In particular, by selectively selecting regulatory T cells and co-culturing them with effector T cells, the present inventors have found that they can inhibit the activity of effector T cells.
  • DKK1 Dickkopf-1
  • the DKK1 is one of the DKK family genes DKK1, DKK2, DKK3, and DKK4, and encodes a secreted protein.
  • the DKK protein generally consists of 255 to 350 amino acids, and in the case of DKK1, has a size of 24 KDa to 29 KDa, and the N-terminus is present in the form of glycosylated sugar.
  • the DKK1 may be represented by the amino acid sequence of SEQ ID NO: 1, and may be encoded by the nucleotide represented by SEQ ID NO: 2 (Table 1).
  • dickkopf-1 (DKK-1) amino acid sequence MMALGAAGAT RVFVAMVAAA LGGHPLLGVS ATLNSVLNSN AIKNLPPPLG GAAGHPGSAV SAAPGILYPG GNKYQTIDNY QPYPCAEDEE CGTDEYCASP TRGGDAGVQI CLACRKRRKR CMRHAMCCPG NYCKNGICVS SDQNHFRGEI EETITESFGN DHSTLDGYSR RTTLSSKMYH TKGQEGSVCL RSSDCASGLC CARHFWSKIC KPVLKEGQVC TKHRRKGSHG LEIFQRCYCG EGLSCRIQKD HHQASNSSRL HTCQRH (SEQ ID NO: 1) dickkopf-1 (DKK-1) mRNA, complete cds (GenBank: AF177394.2) sequence atgatggctc tgggcgcagc gggagctacc cgggtctttg tcgcgatgg
  • the DKK1 binds to a receptor stronger than a ligand such as Wnt3a in the Wnt signaling system involved in cell proliferation and wound recovery, thereby competitively inhibiting Wnt signaling, and thus, in the development of the heart, head, hands, etc. in embryonic development. It can play an important role.
  • the increased secretion protein type DKK1 present in bone marrow plasma can identify osteolytic bone lesions in patients with multiple myeloma and determine the degree of cancer or bone disease. Can be used.
  • the DKK1 may be present on the surface of immune cells, particularly regulatory T cells, without being secreted out of cells as in a general case. This may help immune cells function as regulatory T cells for self tolerance.
  • a regulatory T extracellular surface protein of DKK1 represented by SEQ ID NO: 3 (Table 2).
  • the regulatory T cell extracellular surface protein of DKK1 provided by the present invention may interact with a ligand present in effect T cells to reduce the activity of regulatory T cells.
  • an antigenic epitope of DKK1 which is a surface protein of regulatory T cells, represented by any one of SEQ ID NOs: 4 to 36, is provided (Table 3).
  • the "antigen determinant" is a site that binds the antibody in the antigen molecule, and means a part that can be recognized by the antibody.
  • the antibody does not recognize the entire antigen molecule, but recognizes only a specific part, and even the same antigen molecule can recognize other antigenic determinant parts when the type of the antibody is different.
  • the antigenic determinant is an antigenic determinant of an antibody that can effectively bind to the remaining domains even when a portion of the DKK1 protein exposed to the outside of the cell is cleaved and secreted out of the cell It includes.
  • the polypeptide which is the antigenic determinant may include both a continuous or discontinuous sequence of a portion capable of binding an antibody to the DKK1 protein according to the present invention.
  • polypeptide fragment which is the antigenic determinant of DKK1 which is the surface protein of the regulatory T cells provided by the present invention, may interact with a ligand present in the effect T cells to reduce the activity of the regulatory T cells.
  • an extracellular surface protein of DKK1 represented by SEQ ID NO: 3 provided in the present invention, or a polynucleotide encoding the antigenic determinant of DKK1 of any one of SEQ ID NOs: 4 to 36. .
  • an expression vector into which a polynucleotide provided in the present invention is inserted is provided.
  • the "vector” is the nucleic acid molecule capable of transporting another nucleic acid to which a nucleic acid molecule is linked.
  • a vector which refers to circular double stranded DNA into which additional DNA segments can be ligated.
  • a phage vector Another type of vector is a viral vector, where additional DNA segments can be ligated into the viral genome.
  • Some vectors are capable of autonomous replication in the host cell into which they are introduced (eg, bacterial vectors are episomal mammalian vectors of bacterial replication origin).
  • vectors eg, non-episomal mammalian vectors
  • Other vectors can enter the host cell and integrate into the genome of the host cell, thereby replicating with the host genome.
  • some vectors can direct the expression of the genes to which they are linked in a working dimension.
  • Such vectors are referred to herein as “recombinant expression vectors” or simply "expression vectors.”
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector may be used interchangeably because the plasmid is the most commonly used form of the vector.
  • the expression vector in the present invention include commercially widely used pCDNA vectors, F, R1, RP1, Col, pBR322, ToL, Ti vectors; Cosmid; Phages such as lambda, lambdoid, M13, Mu, p1 P22, Q ⁇ , T-even, T2, T3, T7; It can be selected from the group consisting of plant viruses, but is not limited thereto. All expression vectors known to those skilled in the art as expression vectors can be used in the present invention, and the selection of the expression vector depends on the nature of the host cell of interest.
  • the introduction of the vector into host cells can be performed by calcium phosphate transfection, viral infection, DEAE-dextran controlled transfection, lipofectamine transfection, or electroporation, but is not limited thereto.
  • An introduction method suitable for the expression vector and the host cell can be selected and used.
  • the vector contains one or more selection markers, but is not limited thereto, and may be selected depending on whether the product is produced using a vector that does not include the selection marker.
  • the selection of the selection marker is selected by the host cell of interest, which uses methods already known to those skilled in the art and the present invention is not so limited.
  • tag sequences can be inserted and fused to an expression vector.
  • the tag may include, but is not limited to, a hexa-histidine tag, a hemagglutinin tag, a myc tag, or a flag tag. Any tag that facilitates purification known to those skilled in the art may be used in the present invention.
  • a host cell line transfected with the expression vector provided in the present invention.
  • host cell in the present invention includes individual cells or cell cultures that may or may have been recipients of the vector (s) for incorporation of the polypeptide insert.
  • Host cells include the progeny of a single host cell, which may not necessarily be exactly the same (in morphological or genomic DNA complement) as the original parent cell because of natural, accidental or intentional mutations.
  • Host cells include cells transfected in vivo with the polypeptide (s) herein.
  • the host cell may include cells of mammalian, plant, insect, fungal or cellular origin, for example, bacterial cells such as E. coli, Streptomyces, Salmonella typhimurium; Fungal cells such as yeast cells and peach pastoris; Insect cells such as Drozophila and Spodoptera Sf9 cells; Chinese hamster ovary cells (CHO), SP2 / 0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), 293T, bow melanoma cells, HT-1080, BHK (Baby hamster kidney cells, Baby Hamster Kidney cells), animal cells of HEK (Human Embryonic Kidney cells) or PERC.6 (human retinal cells); Or it may be a plant cell, but is not limited thereto, any cell that can be used as a host cell line known to those skilled in the art is available.
  • bacterial cells such as E. coli, Streptomy
  • a regulatory T cell comprising the extracellular surface protein of the DKK1 or the antigenic determinant of the DKK1 is provided.
  • the regulatory T cells expressing the extracellular surface protein of DKK1 or antigenic determinants thereof on the surface of the present invention may inhibit the cellular activity through interaction with the effect T cells and suppress an immune response.
  • a pharmaceutical composition for preventing or treating an immune related disease comprising an extracellular surface protein of the DKK1 or a regulatory T cell comprising the antigenic determinant of the DKK1 as an active ingredient. do.
  • Regulatory T cells comprising the extracellular surface protein of DKK1 of the present invention may inhibit their cellular activity through interaction with effect T cells and inhibit an immune response.
  • regulatory T cells expressing DKK1 protein on the cell surface are immune-related diseases caused by hyperimmune reactions, for example, autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopic, acute and chronic Inflammatory diseases and the like can be effectively prevented, improved or treated.
  • the DKK1 extracellular surface protein or the antigenic determinant of the present invention as an active ingredient provides a pharmaceutical composition for the prevention or treatment of immune-related diseases.
  • the DKK1 extracellular surface protein or antigenic determinant fragment provided by the present invention interacts with a ligand present in effect T cells to inhibit the activity of regulatory T cells, thereby effectively preventing immune related diseases, for example cancer. Can be improved or treated.
  • the term "cancer” refers to or indicates a physiological condition characterized by unregulated cell growth in mammals.
  • the cancer to be prevented, improved or treated may be a solid tumor composed of agglomerates caused by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, Glioblastoma, ovarian cancer, colorectal cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, and preferably, but not limited to melanoma.
  • a pharmaceutical composition for preventing or treating an immune related disease comprising as an active ingredient an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention.
  • the DKK1 extracellular surface protein may be present on the surface of regulatory T cells.
  • the antibody may inhibit the activity of regulatory T cells to effectively prevent, ameliorate or treat cancer.
  • an antibody refers to a specific protein molecule directed to an antigenic site as it is known in the art.
  • an antibody refers to an antibody that specifically binds to a protein of the present invention, which antibody can be cloned into an expression vector according to a conventional method to produce a protein encoded by the marker gene. Can be obtained and prepared from conventional proteins by conventional methods. Also included are partial peptides that may be made from such proteins, and the partial peptides of the present invention include at least seven amino acids, preferably nine amino acids, more preferably twelve or more amino acids.
  • the form of the antibody of the present invention is not particularly limited and a part thereof is included in the antibody of the present invention and all immunoglobulin antibodies are included as long as they are polyclonal antibody, monoclonal antibody or antigen-binding. Furthermore, the antibody of this invention also contains special antibodies, such as a humanized antibody.
  • Antibodies of the invention include functional fragments of antibody molecules as well as complete forms having two full length light chains and two full length heavy chains.
  • a functional fragment of an antibody molecule refers to a fragment having at least antigen binding function, and includes Fab, F (ab '), F (ab') 2 and Fv.
  • the antibody specifically binds to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells to inhibit the activity of regulatory T cells to effectively prevent immune-related diseases, for example cancer. Can be improved or treated.
  • the cancer may be a solid tumor composed of agglomerates generated by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, glioblastoma, ovarian cancer, and colon cancer , Head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
  • the antibody binds specifically to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells, thereby increasing the activity of regulatory T cells.
  • Disease, graft-versus-host disease, transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, ameliorated or treated.
  • any one selected from the group consisting of antisense oligonucleotides, siRNA, shRNA and microRNA specific to the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant is effective.
  • a pharmaceutical composition for immune-related diseases is provided as an ingredient.
  • the "antisense oligonucleotide” is a short length DNA synthesis strand (or DNA analog) that is antisense (or complementary) to a specific DNA or RNA target, and achieves gene-specific inhibition in vivo as well as in vitro.
  • Used to Antisense oligonucleotides have been proposed to prevent the expression of a protein encoded by a DNA or RNA target by binding to the target and stopping expression at the stage of transcription, translation or splicing.
  • Antisense oligonucleotides have been successfully used in cell culture and animal models of disease.
  • Antisense oligonucleotides as used herein include oligonucleotides having double or single stranded DNA, double or single stranded RNA, DNA / RNA hybrids, DNA and RNA analogs and base, sugar or backbone modifications. Oligonucleotides are modified by methods known in the art to increase stability and to increase resistance to nuclease degradation. These modifications include, but are not limited to, modifications to oligonucleotide backbones, modifications of sugar moieties or bases known in the art.
  • siRNA small interfering RNA
  • siRNA small interfering RNA
  • a double stranded structure or self-complementary sense strand (sequence corresponding to the WLS mRNA sequence) and antisense strand (sequence complementary to the WLS mRNA sequence) is located opposite each other to form a double-chain -complementary
  • sense strand sequence corresponding to the WLS mRNA sequence
  • antisense strand sequence complementary to the WLS mRNA sequence
  • siRNAs are not limited to completely paired double-stranded RNA moieties paired with RNA, but can be paired by mismatch (the corresponding base is not complementary), expansion / protrusion (there is no base corresponding to one chain), and the like. Parts that do not achieve may be included.
  • the siRNA terminal structure can be either a blunt end or a sticky end as long as the expression of the WLS gene can be inhibited by RNA interference (RNAi) effect.
  • RNAi RNA interference
  • the cohesive end structure is possible for both 3'-end protrusion structures and 5'-end protrusion structures.
  • the siRNA molecule is not limited thereto, but may have a total length of 15 to 30 bases, preferably 19 to 21 bases.
  • the "shRNA (short hairpin RNA)" is a single stranded RNA having a length of 45 to 70 nucleotides, and connects 3-10 base linkers between the sense strand of the target gene siRNA sequence and the complementary antisense strand.
  • microRNA regulates various biological processes such as development, differentiation, proliferation, conservation and apoptosis.
  • MicroRNAs generally regulate the expression of the gene encoding the target mRNA by destabilizing the target mRNA or disrupting translation.
  • Regulatory sequences useful in the expression constructs / vectors with the antisense oligonucleotides, siRNAs, shRNAs or microRNAs in the present invention are also known in the art. It may be appropriately selected from the known contents in the following.
  • the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to a gene encoding a DKK1 protein or antigenic determinants thereof expressed on the surface of regulatory T cells to inhibit their expression and immunity.
  • Related diseases can, for example, effectively prevent, ameliorate or treat cancer.
  • the cancer may be a solid tumor composed of agglomerates generated by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, glioblastoma, ovarian cancer, and colon cancer , Head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
  • the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to the gene encoding the DKK1 protein or antigenic determinants expressed on the surface of regulatory T cells to increase their expression. Therefore, as an immune-related disease, for example, autoimmune disease, graft versus host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, improved or treated.
  • prophylaxis may include without limitation any action that blocks, suppresses or delays the symptoms of the disease using the pharmaceutical composition of the present invention.
  • treatment may include without limitation any action that improves or benefits the symptoms of the disease using the pharmaceutical composition of the present invention.
  • the pharmaceutical composition may be characterized in that the capsule, tablets, granules, injections, ointments, powder or beverage form, the pharmaceutical composition may be characterized in that it is intended for humans.
  • the pharmaceutical composition according to the present invention may be prepared in the form of an injection and injected directly to a site where cancer or an immune disease occurs, but is not limited thereto.
  • compositions of the present invention can be used in the form of oral dosage forms, such as powders, granules, capsules, tablets, aqueous suspensions, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers can be used as oral administration binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, fragrances, etc.
  • buffers, preservatives, analgesic Topical agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used, and for topical administration, bases, excipients, lubricants, preservatives and the like can be used.
  • the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable carrier as described above.
  • oral administration may be in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, in the case of injections, in unit dosage ampoules or in multiple dosage forms. have. And other solutions, suspensions, tablets, capsules, sustained release preparations and the like.
  • Suitable carriers, excipients, and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
  • fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like may be further included.
  • Routes of administration of the pharmaceutical compositions according to the invention are not limited to these, but are oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, Sublingual or rectal. Oral or parenteral release is preferred.
  • parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intramuscular, intrasternal, intradural, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical compositions of the invention may also be administered in the form of suppositories for rectal administration.
  • the pharmaceutical compositions of the present invention vary depending on a number of factors, including the activity, age, weight, general health, sex, formulation, time of administration, route of administration, rate of release, drug combination and severity of the particular disease to be prevented or treated, of the specific compound employed.
  • the dosage of the pharmaceutical composition may be appropriately selected by those skilled in the art depending on the patient's condition, weight, degree of disease, drug form, route of administration and duration, and 0.0001 to 50 mg / kg or It may be administered at 0.001 to 50 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
  • the pharmaceutical composition of the present invention may be further administered in combination with other anticancer agents, thereby effectively inhibiting general cancer cell proliferation and cancer metastasis, thereby being used for the treatment of cancer.
  • the anticancer agent is nitrogen mustard, imatinib, oxaliplatin, rituximab, erlotinib, neratinib, lapatinib, zefitinib, vandetanib, nirotinib, semasanib, conservinib, axitinib, cediranib , Restautinib, trastuzumab, gefitinib, bortezomib, sunitinib, carboplatin, sorafenib, bevacizumab, cisplatin, cetuximab, biscumalboom, asparaginase, tretinoin, hydroxycarba Amide, dasatinib, estramastine, gemtuzumab ozogamycin, ibritumab tucetan, heptaplatin, methylaminolevulinic acid, amsacrine, alemtuzumab,
  • the pharmaceutical composition of the present invention may be further administered in combination with other immunosuppressive agents, thereby effectively inhibiting diseases due to general hyperimmune reactions.
  • the immunosuppressive agents include glucocorticoids, cyclophosphamid, cyclosporin, tacrolimu, rapamycin, type IV PDE inhibitors (Type IV PDE inhibitors).
  • type IV PDE inhibitors Type IV PDE inhibitors
  • p38 kinase inhibitors, azathioprine, mycophenolate mofetil, mizoribin, methotrexate, leflunomid, and brequinamide Brequina may be used one or more selected from the group consisting of, but is not limited thereto.
  • a method for preventing or treating an immune related disease comprising administering to a subject in need thereof an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention. It is about.
  • the subject in need of the treatment in the present invention is an individual with an immune related disease or suspected of the symptoms, wherein one example of the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
  • the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
  • the antibody specifically binds to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells to inhibit the activity of regulatory T cells to effectively prevent immune-related diseases, for example cancer. Can be improved or treated.
  • the antibody binds specifically to a DKK1 protein or antigenic determinant thereof expressed on the surface of regulatory T cells, thereby increasing the activity of regulatory T cells.
  • Disease, graft-versus-host disease, transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, ameliorated or treated.
  • a group consisting of antisense oligonucleotides, siRNAs, shRNAs and microRNAs specific for the DKK1 extracellular surface protein of the present invention or a gene encoding the antigenic determinant to a subject in need thereof It relates to a method for preventing or treating an immune related disease, comprising the step of administering any one selected from.
  • the subject in need of the treatment in the present invention is an individual with an immune related disease or suspected of the symptoms, wherein one example of the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
  • the immune related disease is gastric cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, two Cancer, such as cervical cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and other examples include autoimmune diseases, graft versus host disease, organ transplant rejection, asthma, atopy or Acute and chronic inflammatory diseases.
  • the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to a gene encoding a DKK1 protein or antigenic determinants thereof expressed on the surface of regulatory T cells to inhibit their expression and immunity.
  • Related diseases can, for example, effectively prevent, ameliorate or treat cancer.
  • the antisense oligonucleotide, siRNA, shRNA or microRNA specifically binds to the gene encoding the DKK1 protein or antigenic determinants expressed on the surface of regulatory T cells to increase their expression. Therefore, as an immune-related disease, for example, autoimmune disease, graft versus host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases can be effectively prevented, improved or treated.
  • Administration in one embodiment of the invention means introducing the composition of the invention to the patient in any suitable manner, the route of administration of the composition of the invention being administered via any general route as long as it can reach the desired tissue.
  • the method of treatment of the present invention may comprise administering the antibody, antisense oligonucleotide, siRNA, shRNA or microRNA in a pharmaceutically effective amount.
  • the effective amount is defined as the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type and formulation of the patient and the age, body weight, general health condition, sex and diet, time of administration, route of administration And various factors, including the rate of secretion of the composition, the duration of treatment, and the drugs used concurrently.
  • the above-mentioned administration may be administered in combination with another anticancer agent or another immunosuppressant.
  • contacting a sample to be assayed with an extracellular surface protein of DKK1 or a regulatory T cell comprising the antigenic determinant (b) measuring the expression level of said extracellular surface protein or said antigenic determinant; And (c) determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
  • a method for screening an agent or an immunosuppressant is determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
  • the "screening" is to select a substance having a specific characteristic of interest from a candidate group consisting of various substances by a specific manipulation or evaluation method.
  • the screening of the present invention is directed to immunosuppressive or immunosuppressive agents when the expression of a protein of the present invention is reduced or increased after administration of a candidate agent for the treatment of such a disease to a subject suspected of an immune related disease. It is a screening method to discriminate with an activator. Means such as molecular biological assays, digital imaging, cytological and histological examinations can be used to measure the activity of the genes and proteins of the invention on disease pathological or suspicious tissue.
  • the expression level of the extracellular surface protein of the DKK1 or the antigenic determinant, the amount or activity may be carried out using an antibody capable of specifically binding to the extracellular surface protein of the DKK1 or the antigenic determinant.
  • the antibody and the protein of interest in the biological sample form an antigen-antibody complex, and a method of detecting the same is used.
  • the "antigen-antibody complex” means a combination of a protein antigen for identifying the presence or absence of a gene of interest in a biological sample and an antibody which recognizes the same.
  • the detection of the antigen-antibody complex can be detected using methods as known in the art, such as spectroscopic, photochemical, biochemical, immunochemical, electrical, absorbing, chemical and other methods.
  • a method for measuring or comparing the expression level of the protein may include protein chip analysis, immunoassay, ligand binding assay, Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry (MALDI-TOF) analysis, and SELDI-TOF.
  • protein chip analysis immunoassay
  • ligand binding assay ligand binding assay
  • MALDI-TOF Matrix Assisted Laser Desorption / Ionization Time of Flight Mass Spectrometry
  • SELDI-TOF SELDI-TOF
  • contacting a sample to be analyzed with a regulatory T cell comprising the extracellular surface protein of DKK1 or a gene encoding the antigenic determinant (b) measuring the expression level of the gene; And (c) determining that the sample is an immune activator or immunosuppressant when it is determined that the expression level of the gene is reduced or upregulated. It is about.
  • the expression level of the extracellular surface protein of DKK1 or the gene encoding the antigenic determinant may be performed using primers, probes or antisense nucleotides capable of specifically binding to the gene. Since the information of the extracellular surface protein of the DKK1 or the antigenic determinant and the gene encoding the same according to the present invention is known, those skilled in the art based on the primer, probe or antisense nucleotide to specifically bind to the gene encoding the protein It will be easy to design.
  • the primer refers to a short nucleic acid sequence capable of forming a base pair with a complementary template with a nucleic acid sequence having a short free 3-terminal hydroxyl group and serving as a starting point for template strand copying.
  • Primers can initiate DNA synthesis in the presence of four different nucleoside triphosphates and reagents for polymerization (ie, DNA polymerase or reverse transcriptase) at appropriate buffers and temperatures.
  • the PCR can be performed using the sense and antisense primers of genes encoding the extracellular surface protein of DKK1 to diagnose cancer through the generation of desired products. PCR conditions, sense and antisense primer lengths can be modified based on what is known in the art.
  • the probe refers to nucleic acid fragments such as RNA or DNA corresponding to short bases to hundreds of bases capable of specific binding with mRNA, and are labeled to confirm the presence or absence of specific mRNAs.
  • Probes may be prepared in the form of oligonucleotide probes, single stranded DNA probes, double stranded DNA probes, RNA probes and the like.
  • hybridization is performed using a probe complementary to a gene encoding an extracellular surface protein of DKK1, and cancer can be diagnosed through hybridization. Selection of suitable probes and hybridization conditions can be modified based on what is known in the art.
  • Primers or probes of the invention can be synthesized chemically using phosphoramidite solid support methods, or other well known methods. Such nucleic acid sequences can also be modified using many means known in the art. Non-limiting examples of such modifications include methylation, "capsulation", substitution of one or more homologs of natural nucleotides, and modifications between nucleotides, such as uncharged linkages such as methyl phosphonate, phosphoester, Phosphoramidate, carbamate, and the like) or charged linkers (eg, phosphorothioate, phosphorodithioate, etc.).
  • reverse transcriptase polymerase reaction as a method for measuring or comparing the expression level of the gene, reverse transcriptase polymerase reaction, competitive reverse transcriptase polymerase reaction, real time reverse transcriptase polymerase reaction, RNase protection assay, Northern blotting or DNA chip, etc. may be used. May be, but is not limited thereto.
  • the DKK1 extracellular surface protein of the present invention or an antibody specific for the antigenic determinant is provided as an active ingredient, a diagnostic composition for an immune related disease.
  • the diagnosis refers to confirming the presence or characteristic of a pathological state, and for the purpose of the present invention, the diagnosis is to confirm the onset and metastasis of gastric cancer.
  • the DKK1 extracellular surface protein may be present on the surface of regulatory T cells.
  • the immune-related disease can be diagnosed by measuring the expression level of the DKK1 extracellular surface protein or the antigenic determinant present on the surface of regulatory T cells using the antibody.
  • the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
  • the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
  • immune-related including any one selected from the group consisting of primers, probes and antisense nucleotides specific for the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant
  • a composition for diagnosing a disease including any one selected from the group consisting of primers, probes and antisense nucleotides specific for the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant.
  • the DKK1 extracellular surface protein may be present on the surface of regulatory T cells.
  • immune-related diseases can be diagnosed by measuring the expression level of DKK1 extracellular surface protein or the gene encoding the antigenic determinant present on the surface of regulatory T cells using the antibody.
  • the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
  • the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
  • a diagnostic kit for an immune related disease comprising the diagnostic composition of the present invention.
  • the "kit” means a set of compositions and accessories necessary for a specific purpose.
  • the kit of the present invention is a DKK1 extracellular surface protein which is a diagnostic marker for immune related diseases such as cancer, autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases.
  • the disease level can be diagnosed by checking the expression level of mRNA or a protein thereof.
  • Kits of the invention include primers, probes or optionally antibodies that recognize the expression level of a diagnostic marker of an immune related disease, as well as one or more other component compositions, solutions or devices suitable for the assay. Can be.
  • the expression level of the extracellular surface protein or antigenic determinant is measured by using an antibody specific for the extracellular surface protein of DKK1 or the antigenic determinant present in regulatory T cells. It provides a method of providing information about related diseases.
  • the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
  • the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
  • diagnosis of the immune-related disease in the present invention may further comprise the step of administering a therapeutic agent for the immune-related disease.
  • any one selected from the group consisting of primers, probes and antisense nucleotides specific for the gene encoding the DKK1 extracellular surface protein or the antigenic determinant of the present invention in regulatory T cells By measuring the expression level of the gene to provide a method for providing information on immune-related diseases.
  • the immune-related disease may be cancer, more specifically cancer, liver cancer, glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, kidney cell cancer, breast cancer, metastatic cancer, prostate cancer, Pancreatic cancer, melanoma or lung cancer, and the like, preferably may be melanoma, but is not limited thereto.
  • the immune-related diseases may be autoimmune diseases, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute and chronic inflammatory diseases, but are not limited thereto.
  • diagnosis of the immune-related disease in the present invention may further comprise the step of administering a therapeutic agent for the immune-related disease.
  • DKK1 protein is specifically present on the surface of immune cells, especially regulatory T cells, it can be used as a new target of therapeutic agents for various immune related diseases.
  • Figure 1 shows the structure of the DKK1 protein according to an embodiment of the present invention.
  • Figure 2 shows the result of predicting the epitope of the antigen of the DKK1 protein according to an embodiment of the present invention.
  • Figure 3 shows the results of predicting the epitope of the antigen of the DKK1 protein according to an embodiment of the present invention.
  • Figure 4 shows the results of predicting the epitope of the antigen of the DKK1 protein according to an embodiment of the present invention.
  • Figure 5 shows the results of predicting the epitope in the 3S8V chain X of the DKK1 protein according to an embodiment of the present invention.
  • Figure 6 shows the results of predicting the epitope in the 3SOQ chain Z of the DKK1 protein according to an embodiment of the present invention.
  • Figure 7 shows the results of predicting the epitope in the 5FWW chain B of the DKK1 protein according to an embodiment of the present invention.
  • Figure 8 shows the results of predicting the epitope in the 5FWW chain B of the DKK1 protein according to an embodiment of the present invention.
  • Figure 9 shows the expression level of mRNA according to an embodiment of the present invention.
  • Figure 10 shows the expression level of mRNA according to an embodiment of the present invention.
  • FIG. 11 shows the expression of DKK1 protein on the surface of regulatory T cells according to an embodiment of the present invention.
  • a regulatory T extracellular surface protein of DKK1 represented by SEQ ID NO: 3 is provided.
  • an antigenic epitope of DKK1 which is a surface protein of regulatory T cells, represented by any one of SEQ ID NOs: 4 to 36, is provided.
  • an extracellular surface protein of DKK1 represented by SEQ ID NO: 3 provided in the present invention, or a polynucleotide encoding the antigenic determinant of DKK1 of any one of SEQ ID NOs: 4 to 36. .
  • an expression vector into which a polynucleotide provided in the present invention is inserted is provided.
  • a host cell line transfected with the expression vector provided in the present invention.
  • a regulatory T cell comprising the extracellular surface protein of the DKK1 or the antigenic determinant of the DKK1 is provided.
  • a pharmaceutical composition for preventing or treating an immune related disease comprising an extracellular surface protein of the DKK1 or a regulatory T cell comprising the antigenic determinant of the DKK1 as an active ingredient. do.
  • the DKK1 extracellular surface protein or the antigenic determinant of the present invention as an active ingredient provides a pharmaceutical composition for the prevention or treatment of immune-related diseases.
  • a pharmaceutical composition for preventing or treating an immune related disease comprising as an active ingredient an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention.
  • any one selected from the group consisting of antisense oligonucleotides, siRNA, shRNA and microRNA specific to the DKK1 extracellular surface protein of the present invention or the gene encoding the antigenic determinant is effective.
  • a pharmaceutical composition for immune-related diseases is provided as an ingredient.
  • a method for preventing or treating an immune related disease comprising administering to a subject in need thereof an antibody specific for the DKK1 extracellular surface protein or the antigenic determinant of the present invention. It is about.
  • a group consisting of antisense oligonucleotides, siRNAs, shRNAs and microRNAs specific for the DKK1 extracellular surface protein of the present invention or a gene encoding the antigenic determinant to a subject in need thereof It relates to a method for preventing or treating an immune related disease, comprising the step of administering any one selected from.
  • contacting a sample to be assayed with an extracellular surface protein of DKK1 or a regulatory T cell comprising the antigenic determinant (b) measuring the expression level of said extracellular surface protein or said antigenic determinant; And (c) determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
  • a method for screening an agent or an immunosuppressant is determining that the sample is an immune activator or immunosuppressant when the level of expression of the extracellular surface protein or antigenic determinant is measured to be down or upregulated.
  • contacting a sample to be analyzed with a regulatory T cell comprising the extracellular surface protein of DKK1 or a gene encoding the antigenic determinant (b) measuring the expression level of the gene; And (c) determining that the sample is an immune activator or immunosuppressant when it is determined that the expression level of the gene is reduced or upregulated. It is about.
  • the expression level of the extracellular surface protein or antigenic determinant is measured by using an antibody specific for the extracellular surface protein of DKK1 or the antigenic determinant present in regulatory T cells. It provides a method of providing information about related diseases.
  • any one selected from the group consisting of primers, probes and antisense nucleotides specific for the gene encoding the DKK1 extracellular surface protein or the antigenic determinant of the present invention in regulatory T cells By measuring the expression level of the gene to provide a method for providing information on immune-related diseases.
  • DKK1 is known to bind to LRP6, a ligand specific for it, in the form of a secreted protein, so that the amino acid structure of No. 182-266 of the C-terminal portion is important for DKK1 to bind to the ligand, thereby high DKK1 and LRP6 Because of its ability to bind, its binding plays an important role in Wnt cell signaling.
  • the structure of the C-terminal protein of the DKK1 is shown in FIG.
  • DKK1 protein can act as a biomarker specific for regulatory T cells.
  • CD4 + T cells were isolated using magnet-activated cell sorting (MACS) through CD4 beads from the spleen of mice to which C57BL / 6 or Foxp3 and FRP were commonly expressed.
  • MCS magnet-activated cell sorting
  • regulatory T (CD4 + CD25 + T) cells and non-regulated T (CD4 + CD25 ⁇ T) cells were isolated using a fluorescent activated cell sorter (FACS) using a CD25 antibody.
  • FACS fluorescent activated cell sorter
  • Each cell and the cells differentiated in Preparation Example 1 extracted mRNA using Trizol, and genomic RNA removed gDNA by a protocol provided by a company using gDNA extraction kit (Qiagen). .
  • gDNA removed mRNA was synthesized into cDNA through the BDsprint cDNA Synthesis Kit (Clonetech).
  • Real time PCR was performed to quantitatively confirm the expression level of DKK1 mRNA in the cDRNA.
  • the real-time polymerase chain reaction was performed by SYBR Green (Molecular Probes) using a protocol provided by the manufacturer for 3 minutes at 95 °C, 15 seconds at 61 °C, 40 cycles of 30 seconds at 72 °C, Table 4 It was performed using a primer, relative gene expression was calculated using the ⁇ CT method, normalized using HPRT, the results are shown in FIG.
  • the expression of the DKK family gene and the Wnt gene in the regulatory T cells was hardly confirmed, but the expression of the DKK1 gene was remarkably high. It can be seen that it is very likely to be used.
  • DKK1 protein can act as a biomarker specific for regulatory T cells.
  • CD4 + T cells isolated as in Example 3, Treg (CD4 + RFP +) cells, na ⁇ ve T cells, and effector T cells were classified into CD62L antibody (ebioscience) and fluorescent activated cell sorter.
  • CD8 + T cells B cells are separated using an antibody against CD8 ⁇ chain, an antibody against CD19, and then with or without antibodies (ebioscience) to CD3 and CD28, or CD4 + T After culturing in a condition capable of differentiating into cell subtypes, extracting mRNA in the same manner as in Example 3, confirming the expression of DKK1 mRNA, and the results are shown in FIG. 10.
  • the DKK1 gene according to the present invention was higher in regulatory T cells, and in the same regulatory T cells, the group treated with antibodies to CD3 and CD28 had higher expression of DKK1, resulting in differentiation signals. However, the expression of DKK1 was higher in thymus-produced natural Tregs than induced Tregs differentiated into experimental T-cells experimentally.
  • DKK1 protein Since DKK1 protein must be expressed on the surface of regulatory T cells in order to be a target of cell therapy, the target therapy can be more effectively performed. Therefore, it was confirmed whether DKK1 protein is expressed on the surface.
  • Example 4 Each differentiated T cell subtype of Example 4 above was stained with anti-CD4-APC and anti DKK1-PE antibodies and DKK1 at each cell surface using a Fluorescence-Activated Cell Sorter (FACS). The expression amount of was measured and the result is shown in FIG.
  • FACS Fluorescence-Activated Cell Sorter
  • the present invention relates to DKK1 (Dickkopf-1) proteins, antibodies specific thereto, and uses thereof, which are specifically present on the surface of regulatory T cells (Treg cells), among immune cells.
  • DKK1 Dickkopf-1
  • SEQ ID NO: 36 5FWW chain B Discontinuous epitope

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une protéine Dickkopf-1 présente spécifiquement sur la surface de cellules T régulatrices (cellules Treg) parmi des cellules immunitaires, un anticorps spécifique de celle-ci, et une utilisation de celle-ci. Étant présente spécifiquement sur la surface de cellules immunitaires, entre autres, des lymphocytes T régulateurs, la protéine Dickkopf-1 (DKK1) selon la présente invention peut être une nouvelle cible de divers agents thérapeutiques contre des maladies immunitaires.<i />
PCT/KR2018/005398 2017-05-10 2018-05-10 Protéine dkk1 présente spécifiquement dans des lymphocytes t régulateurs et son utilisation WO2018208108A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880031227.9A CN110799212A (zh) 2017-05-10 2018-05-10 特异性存在于调节性t细胞中的dkk1蛋白及其用途
JP2019561863A JP2020519268A (ja) 2017-05-10 2018-05-10 調節ｔ細胞に特異的に存在するｄｋｋ１タンパク質およびその用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20170058337 2017-05-10
KR10-2017-0058337 2017-05-10
KR20170058336 2017-05-10
KR10-2017-0058336 2017-05-10

Publications (1)

Publication Number Publication Date
WO2018208108A1 true WO2018208108A1 (fr) 2018-11-15

Family

ID=64105283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/005398 WO2018208108A1 (fr) 2017-05-10 2018-05-10 Protéine dkk1 présente spécifiquement dans des lymphocytes t régulateurs et son utilisation

Country Status (4)

Country Link
JP (1) JP2020519268A (fr)
KR (1) KR20180123989A (fr)
CN (1) CN110799212A (fr)
WO (1) WO2018208108A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518430A (ja) * 2019-01-15 2022-03-15 バイオニア コーポレーション Ｄｋｋ１遺伝子を標的にする二本鎖オリゴヌクレオチド、これを含む構造体及びこれを含む脱毛予防又は発毛用組成物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220213186A1 (en) * 2019-03-20 2022-07-07 Good T Cells, Inc. Composition for preventing or treating brain and nervous system disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
US20120023600A1 (en) * 2006-01-13 2012-01-26 Janine Shulok Compositions and methods of use for antibodies of dickkopf-1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050084494A1 (en) * 2003-05-21 2005-04-21 Darwin Prockop Inhibitors of Dkk-1
US20120023600A1 (en) * 2006-01-13 2012-01-26 Janine Shulok Compositions and methods of use for antibodies of dickkopf-1

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CHAE, W-J. ET AL.: "Membrane-bound Dickkopf-1 in Foxp3+ Regulatory T Cells Suppresses T- cell -mediated Autoimmune Colitis", IMMUNOLOGY, vol. 152, 27 June 2017 (2017-06-27), pages 265 - 275, XP055568108 *
DATABASE NCBI [O] 6 May 2017 (2017-05-06), "Dickkopf-related Protein 1 Precursor [Homo sapiens", XP055559631, Database accession no. NP_036374.1 *
QIAN, J. ET AL.: "Dickkopf-1 (DKK1) Is a Widely Expressed and Potent Turnor-associated Antigen in Multiple Myeloma", BLOOD, vol. 110, no. 5, 2007, pages 1587 - 1594, XP055568100 *
QIAN, J. ET AL.: "DKK1 as a Novel Target for Myeloma Immunotherapy", ONCOIMMUNOLOGY, vol. 1, no. 5, 2012, pages 756 - 758, XP055568094 *
RK GERSHONK. KONDO, IMMUNOLOGY, vol. 18, 1970, pages 723 - 37
ZHANG, X. ET AL.: "Designation of a Novel DKK1 Multiepitope DNA Vaccine and Inhibition of Bone Loss in Collagen-induced Arthritic Mice", BIOMED RESEARCH INTERNATIONAL, vol. 2015, 2015, pages 1 - 9, XP055568092 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022518430A (ja) * 2019-01-15 2022-03-15 バイオニア コーポレーション Ｄｋｋ１遺伝子を標的にする二本鎖オリゴヌクレオチド、これを含む構造体及びこれを含む脱毛予防又は発毛用組成物
JP7356505B2 (ja) 2019-01-15 2023-10-04 バイオニア コーポレーション Ｄｋｋ１遺伝子を標的にする二本鎖オリゴヌクレオチド、これを含む構造体及びこれを含む脱毛予防又は発毛用組成物

Also Published As

Publication number Publication date
CN110799212A (zh) 2020-02-14
KR20180123989A (ko) 2018-11-20
JP2020519268A (ja) 2020-07-02

Similar Documents

Publication Publication Date Title
WO2019124951A9 (fr) Inhibiteurs d&#39;hétéromères gpcr et leurs utilisations
WO2015005632A1 (fr) Nouvelles protéines à double cible se liant spécifiquement à dll4 et vegf et leur utilisation
WO2020032784A1 (fr) Liaison du récepteur antigénique chimérique à hla-dr, et cellule car-t
WO2020005003A1 (fr) Anticorps monoclonal se liant de manière spécifique à lag-3 et son utilisation
WO2018208108A1 (fr) Protéine dkk1 présente spécifiquement dans des lymphocytes t régulateurs et son utilisation
WO2021091359A1 (fr) Épitope d&#39;antigène de surface de lymphocyte t régulateur, et anticorps se liant de manière spécifique à celui-ci
WO2023096126A1 (fr) Procédé de criblage d&#39;inhibiteur de mdsc
WO2023277361A1 (fr) Anticorps spécifiques de la mésothéline et leur utilisation
WO2019194586A1 (fr) Nouvelle cible pour lutter contre le cancer et renforcer l&#39;immunité
WO2019216675A1 (fr) Épitope d&#39;antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci
WO2016126071A1 (fr) Ribozyme de trans-épissage ciblant ctla-4 pour administration de récepteurs antigéniques chimériques, et son utilisation
WO2022216066A1 (fr) Biomarqueur pour l&#39;estimation du pronostic chez des patients atteints de cancer et son utilisation
WO2014038890A1 (fr) Protéine de fusion comprenant axl et composition pour le traitement du cancer la comprenant
WO2010137770A1 (fr) Nouvelle protéine gpcr et son utilisation
WO2022131889A1 (fr) Utilisation de protéine taci
WO2010126279A2 (fr) Anticorps humain spécifique de la cytokératine 17
WO2017061828A1 (fr) Composition pharmaceutique pour prévenir ou traiter un cancer comprenant un inhibiteur de plrg1 (régulateur pléiotropique 1) comme principe actif
WO2014021693A2 (fr) Anticorps monoclonal inédit se liant spécifiquement à la protéine tm4sf5 et son utilisation
KR101026016B1 (ko) Ｔ 세포 접착 분자 및 이에 대한 항체
WO2017030395A1 (fr) Composition pharmaceutique pour le traitement ou la prévention de l&#39;obésité
WO2021112640A1 (fr) Anticorps anti-tm4sf4 et son utilisation
WO2023277281A1 (fr) Anticorps humanisé spécifique de cd47 et composition pharmaceutique le comprenant pour prévenir ou traiter une maladie liée à cd47
WO2022124764A1 (fr) Anticorps spécifique de cd47 et son utilisation
WO2017164486A1 (fr) Composition pour inhiber la résistance à des agents anticancéreux, contenant un inhibiteur de tesk1, et procédé de criblage d&#39;un inhibiteur de tesk1
WO2022220648A1 (fr) Récepteur chimérique à l&#39;antigène spécifique de hla-dr, et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18799358

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2019561863

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018799358

Country of ref document: EP

Effective date: 20191210

122 Ep: pct application non-entry in european phase

Ref document number: 18799358

Country of ref document: EP

Kind code of ref document: A1